This PROVIDER ALERT contains important information regarding concerns potentially impacting resident healthcare:

- Burkholderia cepacia outbreaks possible link to liquid docusate; and
- Recall of Alere INRatio PT/INR Monitor System

**Burkholderia cepacia (B. cepacia)**

There have been reports of multistate outbreak of B. cepacia infections. The CDC and the FDA is currently investigating.

Preliminary reports indicate that *contaminated oral liquid docusate* product may be related to cases in one state involved in the outbreak. Until more information is available, CDC officials are recommending that health care facilities not use any oral liquid docusate products until the CDC and the FDA have completed their investigation.

Facilities with any resident identified with B. cepacia who has used oral liquid docusate stool softener are requested to contact Lisa Takeuchi, an Epidemiologist with the Oregon Public Health Division, at lisa.c.takeuchi@state.or.us and to save all docusate products used in the facility. Recommendations for infection control measures will be provided at that time.
Infections caused by B. cepacia frequently are resistant to multiple antibiotics and can be life-threatening. Persons most susceptible are those who are immunocompromised, critically ill, have chronic respiratory illness, especially those with cystic fibrosis or on ventilation.

This is an important reminder for care providers to always practice meticulous hand hygiene and to follow standard infection control practices, such as gloving when contact with mucous membranes or body fluids or items contaminated is anticipated.

Alere INRatio PT/INR Monitor System

Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc. (NYSE:ALR) will be initiating a voluntary withdrawal of the Alere INRatio and INRatio2 PT/INR Monitoring System. Alere is working with the FDA to determine the most appropriate timing for product discontinuation and will provide guidance on transitioning patients to an alternate solution to allow them to continue anti-coagulation monitoring in the least disruptive manner possible.

For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, go to: http://www.fda.gov/Safety/Recalls/ucm510746.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery.

If a resident uses PT/INR testing using “Alere” monitor system please share this Provider ALERT with the resident’s healthcare provider or prescriber for follow-up directions regarding INR testing.